| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
41,691 |
38,210 |
$5.63M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
33,390 |
29,373 |
$4.10M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
6,799 |
6,402 |
$1000K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,763 |
1,488 |
$495K |
| 80053 |
Comprehensive metabolic panel |
29,512 |
23,615 |
$451K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
203 |
195 |
$266K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
976 |
413 |
$179K |
| 80197 |
|
4,212 |
2,246 |
$125K |
| 95782 |
|
142 |
135 |
$123K |
| 84484 |
|
5,652 |
4,316 |
$95K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
417 |
383 |
$84K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
452 |
441 |
$70K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,822 |
3,329 |
$70K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
902 |
813 |
$65K |
| 70450 |
Computed tomography, head or brain; without contrast material |
355 |
316 |
$63K |
| 81001 |
|
15,889 |
13,229 |
$53K |
| 85027 |
|
40,027 |
32,247 |
$46K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
55 |
53 |
$45K |
| 30140 |
|
12 |
12 |
$34K |
| 83735 |
|
5,147 |
2,812 |
$32K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
449 |
398 |
$29K |
| 31622 |
|
69 |
63 |
$28K |
| 87496 |
|
946 |
544 |
$27K |
| 80069 |
|
814 |
543 |
$26K |
| 76770 |
|
169 |
164 |
$26K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,098 |
1,930 |
$20K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
14 |
13 |
$19K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
261 |
253 |
$15K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
226 |
204 |
$14K |
| 85610 |
|
3,906 |
2,515 |
$14K |
| 80320 |
|
121 |
100 |
$12K |
| 82570 |
|
2,148 |
1,446 |
$11K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,324 |
923 |
$10K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
16,098 |
14,306 |
$8K |
| 96112 |
|
18 |
16 |
$7K |
| 82977 |
|
4,399 |
2,361 |
$7K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,967 |
1,881 |
$7K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
57 |
50 |
$5K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
106 |
93 |
$4K |
| 82105 |
|
101 |
92 |
$4K |
| 83970 |
|
201 |
191 |
$4K |
| 84100 |
|
5,019 |
2,756 |
$3K |
| 84156 |
|
2,097 |
1,443 |
$3K |
| 74170 |
|
18 |
13 |
$3K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,725 |
1,605 |
$2K |
| 42975 |
|
25 |
24 |
$2K |
| 82728 |
|
121 |
114 |
$2K |
| 11043 |
|
25 |
13 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
5,796 |
5,127 |
$1K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
922 |
562 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
12 |
12 |
$1K |
| 83540 |
|
125 |
118 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,427 |
7,218 |
$858.41 |
| 82043 |
|
13 |
13 |
$794.72 |
| 71046 |
Radiologic examination, chest; 2 views |
616 |
575 |
$710.29 |
| 83550 |
|
124 |
117 |
$685.18 |
| 83880 |
|
13 |
12 |
$653.30 |
| 83615 |
|
335 |
182 |
$544.06 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,091 |
3,571 |
$491.48 |
| G0378 |
Hospital observation service, per hour |
39 |
16 |
$478.79 |
| Q3014 |
Telehealth originating site facility fee |
105 |
96 |
$348.13 |
| 84550 |
|
293 |
156 |
$208.05 |
| 80076 |
|
13 |
12 |
$187.09 |
| 82077 |
|
1,805 |
1,553 |
$151.40 |
| 82465 |
|
134 |
78 |
$143.22 |
| 81003 |
|
116 |
65 |
$122.01 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,207 |
2,037 |
$85.48 |
| 85730 |
|
45 |
37 |
$79.52 |
| 83690 |
|
6,065 |
5,439 |
$78.08 |
| 82040 |
|
13 |
13 |
$56.36 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
799 |
489 |
$54.24 |
| 84703 |
|
4,902 |
4,472 |
$22.80 |
| 84702 |
|
375 |
344 |
$11.20 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,400 |
3,103 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
977 |
905 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
14 |
14 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
429 |
391 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
126 |
95 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
801 |
521 |
$0.00 |
| 80306 |
|
178 |
143 |
$0.00 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
12 |
12 |
$0.00 |
| 74018 |
|
152 |
144 |
$0.00 |
| 81025 |
|
131 |
117 |
$0.00 |
| 82075 |
|
144 |
122 |
$0.00 |
| 82248 |
|
42 |
40 |
$0.00 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
100 |
87 |
$0.00 |
| 96113 |
|
18 |
16 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
15 |
14 |
$0.00 |
| 88304 |
|
159 |
157 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
516 |
495 |
$0.00 |
| 87081 |
|
394 |
367 |
$0.00 |
| 87430 |
|
781 |
738 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
273 |
182 |
$0.00 |
| 86140 |
|
188 |
183 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
27 |
25 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
14 |
14 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
90 |
89 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
51 |
48 |
$0.00 |
| 83605 |
|
30 |
24 |
$0.00 |
| 86780 |
|
13 |
13 |
$0.00 |
| 85379 |
|
13 |
13 |
$0.00 |